Results 21 to 30 of about 36,256 (261)

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Albumin Levels Are Predictive of Cachexia-Induced Time-Dependent Clearance of Therapeutic Antibodies: A Physiologically Based Pharmacokinetic Model of Durvalumab. [PDF]

CPT Pharmacometrics Syst Pharmacol
ABSTRACT Cachexia is a metabolic condition that accelerates the clearance of monoclonal antibodies in cancer patients and is a known mechanism causing time‐dependent clearance. Successful anticancer treatment often ameliorates symptoms of cachexia, reducing the drug clearance over time especially in patients who respond. Serum albumin level is a common
Proctor JR, Wong H.
europepmc   +2 more sources

Chemoradiation followed by adjuvant durvalumab in stage III non–small cell lung cancer: Real‐world comparison of treatment outcomes to historical controls treated with chemoradiation alone

Thoracic Cancer, 2022
Objective Compare outcomes in patients with stage III non–small cell lung cancer (NSCLC) treated with chemoradiation and adjuvant durvalumab to historical controls treated with chemoradiation alone.
Akram Saad, Jeffrey Goldstein, Sarit Appel, Sameh Daher, Damien Urban, Amir Onn, Hadas Gantz‐Sorotsky, Anastasiya Lobachov, Teodor Gottfried, Benjamin Spieler, Jair Bar   +10 more
doaj   +1 more source

Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression

Current Oncology, 2023
Adjuvant durvalumab after chemoradiotherapy (CRT) is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). A post hoc exploratory analysis of PACIFIC revealed no OS benefit in the PD-L1 < 1% subgroup.
Marie-Hélène Denault, Jamie Feng, Shelley Kuang, Aria Shokoohi, Bonnie Leung, Mitchell Liu, Eric Berthelet, Janessa Laskin, Sophie Sun, Tina Zhang, Cheryl Ho, Barbara Melosky   +11 more
doaj   +1 more source

PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. [PDF]

, 2016
A new approach to the management of non-small-cell lung cancer (NSCLC) has recently emerged that works by manipulating the immune checkpoint controlled by programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1).
Booton, R, Cane, P, Cree, IA, Gosney, J, Ibrahim, M, Kerr, K, Lal, R, Lewanski, C, Navani, N, Nicholson, AG, Nicolson, M, Summers, Y   +11 more
core   +2 more sources

Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer

Radiation Oncology, 2022
Background Concurrent chemoradiotherapy (CCRT) followed by durvalumab is the standard of care for unresectable locally-advanced non-small cell carcinoma (LA-NSCLC).
Hiroshi Mayahara, Kazuyuki Uehara, Aya Harada, Keiji Kitatani, Tomonori Yabuuchi, Shuichirou Miyazaki, Takeaki Ishihara, Hiroki Kawaguchi, Hikaru Kubota, Hideaki Okada, Taira Ninomaru, Chihiro Shindo, Akito Hata   +12 more
doaj   +1 more source

Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study

Vaccines, 2021
Background: The experience of using consolidation durvalumab in post-concurrent chemoradiation (CCRT) unresectable stage III non-small cell lung cancer (NSCLC) is rare in real-world clinical practice, and the factors associated with its efficacy are also
Chin-Chou Wang, Li-Chung Chiu, Jia-Shiuan Ju, Yu-Ching Lin, Yueh-Fu Fang, Cheng-Ta Yang, Ping-Chih Hsu   +6 more
doaj   +1 more source

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. [PDF]

, 2017
The major development of the past decade in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was the introduction of cetuximab in combination with platinum plus 5-fluorouracil chemotherapy ...
Ana Ferreira Castro, Athanassios Argiris, Athanassios Argiris, Jeltje Schulten, Kevin J. Harrington, Lisa Licitra, Makoto Tahara, Pauline Chomette   +7 more
core   +3 more sources

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC

JTO Clinical and Research Reports, 2022
Introduction: Durvalumab after concurrent chemoradiation (CCRT) for NSCLC improves survival, but only in a subset of patients. We investigated the effect of severe radiation-induced lymphopenia (sRIL) on survival in these patients.
Wang Jing, MD, Ting Xu, PhD, Lirong Wu, MD, Pablo B. Lopez, MD, Clemens Grassberger, PhD, Susannah G. Ellsworth, MD, Radhe Mohan, PhD, Brian P. Hobbs, PhD, George R. Blumenschein, MD, Janet Tu, MD, Mehmet Altan, MD, Percy Lee, MD, Zhongxing Liao, MD, Steven H. Lin, MD, PhD   +13 more
doaj   +1 more source

Potential role of immunotherapy in advanced non-small-cell lung cancer [PDF]

, 2016
Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib ...
Antoniou, Georgios, Catarina, Paulo Esrom, De Mello, Ramon Andrade, Nadine, Sara, Veloso, Ana Flavia   +4 more
core   +3 more sources